Assessment of and Interventions for Women at High Risk for Breast or Ovarian Cancer: A Survey of Primary Care Physicians.
Adult
Aged
Breast Neoplasms
/ diagnosis
Clinical Competence
/ statistics & numerical data
Cross-Sectional Studies
Early Detection of Cancer
/ methods
Female
Humans
Male
Middle Aged
Ovarian Neoplasms
/ diagnosis
Physicians, Primary Care
/ standards
Practice Guidelines as Topic
Practice Patterns, Physicians'
/ standards
Risk Assessment
/ standards
Risk Factors
Surveys and Questionnaires
/ statistics & numerical data
United States
Journal
Cancer prevention research (Philadelphia, Pa.)
ISSN: 1940-6215
Titre abrégé: Cancer Prev Res (Phila)
Pays: United States
ID NLM: 101479409
Informations de publication
Date de publication:
02 2021
02 2021
Historique:
received:
31
07
2020
revised:
16
09
2020
accepted:
02
10
2020
pubmed:
8
10
2020
medline:
8
2
2022
entrez:
7
10
2020
Statut:
ppublish
Résumé
As clinical guidelines for cancer prevention refer individuals to primary care physicians (PCP) for risk assessment and clinical management, PCPs may be expected to play an increasing role in cancer prevention. It is crucial that PCPs are adequately supported to assess an individual's cancer risk and make appropriate recommendations. The objective of this study is to assess use, familiarity, attitude, and behaviors of PCPs regarding breast and ovarian cancer risk and prevention, to better understand the factors that influence their prescribing behaviors. We conducted a cross-sectional, web-based survey of PCPs in the United States, recruited from an opt-in healthcare provider panel. Invitations were sent in batches until the target sample size of 750 respondents (250 each for obstetrics/gynecology, internal medicine, and family medicine) was met. Self-reported use of breast/ovarian cancer risk assessments was low (34.7%-59.2%) compared with discussion of cancer family history (96.9%), breast exams (87.1%), and mammograms (92.8%). Although most respondents (48.0%-66.8%) were familiar with cancer prevention interventions, respondents who reported to be less familiar were more likely to report cautious attitudes. When presented with hypothetical cases depicting patients at different breast/ovarian cancer risks, up to 34.0% of respondents did not select any of the clinically recommended course(s) of action. This survey suggests that PCP use of breast/ovarian cancer risk assessment tools and ability to translate the perceived risks to clinical actions is variable. Improving implementation of cancer risk assessment and clinical management guidelines within primary care may be necessary to improve the appropriate prescribing of cancer prevention interventions.
Identifiants
pubmed: 33023915
pii: 1940-6207.CAPR-20-0407
doi: 10.1158/1940-6207.CAPR-20-0407
pmc: PMC8021601
mid: NIHMS1636664
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
205-214Subventions
Organisme : NCI NIH HHS
ID : HHSN261201400002B
Pays : United States
Organisme : NCI NIH HHS
ID : HHSN261201400002C
Pays : United States
Organisme : Intramural NIH HHS
ID : Z99 CA999999
Pays : United States
Informations de copyright
©2020 American Association for Cancer Research.
Références
Am J Med. 2020 Jun;133(6):723-732
pubmed: 31862335
Ann Surg Oncol. 2015 Oct;22(10):3230-5
pubmed: 26202562
JAMA. 2018 Feb 13;319(6):588-594
pubmed: 29450531
JAMA. 2019 Aug 20;322(7):652-665
pubmed: 31429903
J Clin Oncol. 2020 Apr 10;38(11):1222-1245
pubmed: 31986064
Cancer Prev Res (Phila). 2010 Jun;3(6):696-706
pubmed: 20404000
J Natl Compr Canc Netw. 2015 Jul;13(7):927-35
pubmed: 26150584
Breast Cancer Res Treat. 2018 Sep;171(2):435-442
pubmed: 29808287
Cancer Prev Res (Phila). 2010 Jun;3(6):686-8
pubmed: 20522798
BMC Health Serv Res. 2018 Aug 13;18(1):633
pubmed: 30103738
N Engl J Med. 2011 Jun 23;364(25):2381-91
pubmed: 21639806
Clin Obstet Gynecol. 2017 Dec;60(4):738-757
pubmed: 28957949
Am J Prev Med. 2010 Jan;38(1):110-7
pubmed: 20117566
J Natl Cancer Inst. 2007 May 2;99(9):727-37
pubmed: 17470740
J Clin Oncol. 2019 Nov 20;37(33):3152-3165
pubmed: 31479306
JAMA. 2006 Jun 21;295(23):2727-41
pubmed: 16754727
Cancer. 2004 Sep 1;101(5 Suppl):1165-87
pubmed: 15329892
N Engl J Med. 2006 Jul 13;355(2):125-37
pubmed: 16837676
Patient Educ Couns. 2017 Dec;100(12):2346-2354
pubmed: 28734560
JAMA. 2019 Sep 3;322(9):857-867
pubmed: 31479144
BMC Health Serv Res. 2019 Jul 31;19(1):534
pubmed: 31366355
Eur J Breast Health. 2018 Apr 01;14(2):64-71
pubmed: 29774312
J Natl Compr Canc Netw. 2020 Apr;18(4):380-391
pubmed: 32259785
BMJ. 1998 Aug 15;317(7156):465-8
pubmed: 9703533
J Natl Cancer Inst. 2009 Jan 21;101(2):80-7
pubmed: 19141781
Lancet. 2008 Jan 26;371(9609):303-14
pubmed: 18294997
Am J Prev Med. 2008 Jul;35(1 Suppl):S67-74
pubmed: 18541190
Ann Intern Med. 2016 Feb 16;164(4):279-96
pubmed: 26757170
J Natl Compr Canc Netw. 2018 Nov;16(11):1362-1389
pubmed: 30442736
J Clin Oncol. 2010 Jun 20;28(18):3090-5
pubmed: 20458026
J Natl Cancer Inst. 2014 Jun;106(6):dju091
pubmed: 24824314
JAMA. 1999 Jun 16;281(23):2189-97
pubmed: 10376571
Ann Oncol. 2016 Apr;27(4):575-90
pubmed: 26646754
Cancer Prev Res (Phila). 2019 Apr;12(4):271-282
pubmed: 30824471
J Natl Cancer Inst. 2007 Feb 21;99(4):283-90
pubmed: 17312305
JAMA. 2015 Oct 20;314(15):1599-614
pubmed: 26501536
J Natl Cancer Inst. 2007 Feb 21;99(4):272-82
pubmed: 17312304
BMC Med Inform Decis Mak. 2018 Dec 17;18(1):134
pubmed: 30558581
Cancer. 2015 Jul 1;121(13):2108-20
pubmed: 25820366
Obstet Gynecol. 2017 Sep;130(3):e110-e126
pubmed: 28832484
Obstet Gynecol. 2017 Jul;130(1):e1-e16
pubmed: 28644335
Am J Hum Genet. 2003 May;72(5):1117-30
pubmed: 12677558
BMC Med Inform Decis Mak. 2014 Jan 14;14:4
pubmed: 24422989
NPJ Breast Cancer. 2017 May 19;3:20
pubmed: 28649660
JAMA. 1995 Sep 6;274(9):700-5
pubmed: 7650822